• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Check-Cap Ltd.

    10/16/25 5:15:01 PM ET
    $CHEK
    Medical Electronics
    Health Care
    Get the next $CHEK alert in real time by email
    6-K 1 ea0261544-6k_check.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of October 2025

     

    Commission File Number: 001-36848

     

    Check-Cap Ltd.

    (Exact Name of Registrant as Specified in Charter)

     

    Abba Hushi Avenue

    P.O. Box 1271

    Isfiya, 30090 Mount Carmel, Israel

    (Address of principal executive offices)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒ Form 40-F ☐

     

     

     

     

     

     

    This Form 6-K is being incorporated by reference into Check-Cap Ltd.’s Registration Statements on Form F-3 (File No. 333-262401) and Form S-8 (File No. 333-203384, 333-226490 and 333-259666) filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    1

     

     

    This Form 6-K is being filed to provide several updates on the business of Check-Cap Ltd. (the “Company”).

     

    Key Highlights

     

    ●Significant post-announcement market momentum: the Company is among the most active movers on Nasdaq, with the share price increasing by more than 300% and trading volumes in the hundreds of millions of dollars.

     

    ●Strong institutional interest: dozens of leading investors and investment banks expressed immediate interest in participating in the Company’s growth strategy.

     

    ●Regained compliance: Nasdaq confirmed the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2); the matter is closed.

     

    ●Strategic flexibility: due to overwhelming interest, the Board of Directors of the Company (the “Board”) is evaluating potential investments intended to strengthen the balance sheet and accelerate growth.

     

    Corporate and Market Update

     

    Following the announcement of the Company’s entry into an Agreement and Plan of Merger with MBody AI, a Nevada corporation, the Company experienced exceptional inbound engagement from the capital markets. Institutional investors and investment banks, numbering in the dozens, expressed strong and immediate interest in supporting the combined company’s growth strategy. Concurrently, the Company was one of the most active movers on Nasdaq, with the share price increasing by more than 300% and aggregate trading volumes reaching the hundreds of millions of dollars in the days following the announcement. This momentum reflects robust investor confidence in the merger and MBody AI’s continued, astonishing growth trajectory.

     

    Nasdaq Compliance Update

     

    ●As previously disclosed, on April 9, 2025, the Company received a deficiency letter from the Nasdaq Listing Qualifications Department regarding the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). On September 29, 2025, Nasdaq notified the Company that it had regained compliance as a result of the closing bid price of its ordinary shares being $1.00 per share or greater for ten consecutive trading days. Accordingly, this matter is now closed.

     

    ●Based on its consolidated unaudited financial statements for the six months ended June 30, 2025, the Company believes its stockholders’ equity significantly exceeds $2,500,000, well above the minimum required under Nasdaq Listing Rule 5550(b)(1) (the “Equity Rule”) and, accordingly, that it is in compliance with the Equity Rule. The Company has prepared these financial statements and will be filing them with the Securities and Exchange Commission in due course. As previously disclosed, on September 3, 2025, the Company received a deficiency letter from the Nasdaq Listing Qualifications Department regarding its noncompliance with the Equity Rule; however, in light of the foregoing, the Company believes the deficiency has been remedied. The Company awaits formal confirmation from Nasdaq and will update the market promptly upon receipt of Nasdaq’s compliance determination.

     

    2

     

     

    Financing and Strategic Considerations

     

    In response to the significant and constructive market interest in the merged MBody AI and Check-Cap company, the Board is actively evaluating potential financing opportunities to fortify the merged company’s capital position and accelerate execution of its growth strategy. No securities are being offered by this Form 6-K, and any potential financing would be conducted in compliance with applicable laws and regulations.

     

    Merger and Growth Outlook

     

    MBody AI continues to demonstrate strong operating momentum. The Company believes the combined platform is well-positioned to deliver market-leading capabilities, supported by substantial investor engagement and strategic optionality.

     

    Annual General Meeting of Shareholders – Rescheduling Notice

     

    To accommodate the exceptional level of investor engagement and to provide additional time to evaluate the aforementioned financing opportunities, the Company has determined to reschedule its Annual General Meeting (“AGM”) of Shareholders (originally scheduled for October 17, 2025). The recent U.S. government shutdown has also impacted timing and logistics. The Company expects to furnish a further Form 6-K announcing the updated AGM date, time and record date within the next few weeks.

     

    Forward-Looking Statements

     

    This Report on Form 6-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding potential financing transactions, the anticipated benefits of the proposed merger, market positioning, and timing of the rescheduled AGM. These forward-looking statements are based on current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described. For a discussion of these and other risks, please refer to the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.

     

    3

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      CHECK-CAP LTD.
      (Registrant)
         
    Date: October 16, 2025 By: /s/ David Lontini
      Name:  David Lontini
      Title: Interim Chief Executive Officer

     

    4

     

    Get the next $CHEK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CHEK

    DatePrice TargetRatingAnalyst
    8/9/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CHEK
    SEC Filings

    View All

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    11/4/25 5:16:13 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    10/16/25 5:15:01 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form 6-K filed by Check-Cap Ltd.

    6-K - Check-Cap Ltd (0001610590) (Filer)

    9/12/25 4:38:16 PM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MBody AI and Check-Cap Enter into Definitive Merger Agreement

    Merger to Create Combined Company Focused on Embodied AI for the Autonomous Workforce ISFIYA, ISRAEL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- MBody AI ("MBody AI") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Agreement and Plan of Merger (the "Merger"). If the Merger is approved by Check-Cap shareholders, it will create a combined company focused on embodied AI for the autonomous workforce. Check-Cap's legacy business will continue its research and development activities as part of the combined company. MBody AI is a market-leading artificial intelligence ("AI") company redefining the future of work through embodied

    9/12/25 5:39:51 PM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap claims BMO's Chris Taves Illegally Attacks Israeli NASDAQ-Listed Company During Wartime

    Check-Cap Ltd. Issues Strong Condemnation of MediPharm Labs Chairman Chris Taves for Fabricated Defamatory Statements Press Releases Taves Times his Attack to Commence 23 Minutes before the Start of Shabbat to Delay the Company from Responding ISFIYA, ISRAEL, June 04, 2025 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ:CHEK) ("Check-Cap" or the "Company"), a clinical-stage medical diagnostics company incorporated in Israel, today publicly condemned MediPharm Labs Corp. (LABS) ("MediPharm Labs") and its Chairman, Chris Taves, Head of Asia for BMO Capital Markets, for disseminating derogatory, false, and misleading statements about Check-Cap during a profoundly sensitive and challenging time

    6/4/25 7:00:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

    Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex

    5/14/25 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

    HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $3.00 from $4.00 previously

    8/9/21 6:35:25 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap downgraded by Dawson James with a new price target

    Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00

    3/17/21 12:12:30 PM ET
    $CHEK
    Medical Electronics
    Health Care

    HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

    HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $4.00 from $1.50 previously

    3/16/21 6:31:50 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Leadership Updates

    Live Leadership Updates

    View All

    Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting

    Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental.  Symetryx discusses its concerns around the actions of the Board in its evaluation

    11/28/23 11:56:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Check-Cap Appoints Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs

    ISFIYA, Israel, Sept. 1, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and implementation as well as driving the Company's clinical direction, including innovation. "Dr. Brenner-Lavie has a proven track record of clinical strategy dev

    9/1/21 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

    4/8/24 7:35:32 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form SC 13D filed by Check-Cap Ltd.

    SC 13D - Check-Cap Ltd (0001610590) (Subject)

    4/1/24 9:26:38 PM ET
    $CHEK
    Medical Electronics
    Health Care

    SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

    SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

    12/18/23 6:07:13 AM ET
    $CHEK
    Medical Electronics
    Health Care

    $CHEK
    Financials

    Live finance-specific insights

    View All

    Apollo Technology Capital Corporation Poses Questions That MediPharm Shareholders Should Ask on Management's Conference Call with Shareholders

    Company Has Suspended Calls Since the Second Quarter of 2024 to Avoid Facing the Music for Board's and Management Team's Destruction of 99% of Stock's Value, Costing Shareholders $1 Billion  Conference Call is a Blatant, Self-Serving Reaction by a Management Team Running Scared Following Apollo Capital's Intention to Nominate Six Highly Qualified Directors to MediPharm's Board  Shareholders Deserve Answers From Management About Massive Underperformance, Failed Operational Strategies, Poor Capital Allocation, Outrageous Compensation, and Lack of Transparency Apollo Capital's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Ex

    5/14/25 8:30:00 AM ET
    $CHEK
    Medical Electronics
    Health Care

    Keystone Dental Group Granted Patent from USPTO for Nexus IOS Solution

    IRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings ("Keystone Dental" or the "Company"), today announced the United States Patent and Trademark Office (USPTO) has granted the Company a patent for its innovative Nexus IOS solution. The Nexus iOS Scan Gauge technology allows implant dentists to perform direct full-arch implant scans using an Intraoral Scanner (IOS) with predictable and passive fitting prosthetic outcomes. This technology replaces the traditionally manual impression-taking process through a faster, cost-effective, and accessible workflow. The Nexus iOS Scan Gauge technology is now the only patented elongated body scan

    10/18/23 4:05:00 PM ET
    $CHEK
    Medical Electronics
    Health Care

    Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement

    Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions Keystone 2022 revenues exceeded $60 million The combined company will trade on the NASDAQ with the ticker "KSD" Investor conference call and webcast scheduled for 8:30 a.m. ET on Thursday, August 17th IRVINE, Calif. and BURLINGTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings, Inc. ("Keystone Dental") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Busin

    8/16/23 5:08:47 PM ET
    $CHEK
    Medical Electronics
    Health Care